Reporte zur Charge Ej1685 first do

Symptomtext

COVID test positive; COVID test positive; Vaccine brand other: Moderna Bivalent/ vaccine brand: Pfizer / BioNTech; This is a spontaneous report received from a contactable reporter(s) (Physician) from product quality group. The reporter is the patient. A 69-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 16Dec2020 as dose 1, single (Lot number: E1685), in left arm, on 07Jan2021 as dose 2, single (Lot number: EJ1686), in left arm, on 09Oct2021 as dose 3 (booster), single (Lot number: 30145BA), in left arm and on 26May2022 as dose 4 (booster), single (Lot number: FN2908), in left arm for covid-19 immunisation; davesomeran, elasomeran (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)), on 02Nov2022 as dose 5 (booster), single (Lot number: 016H22A), in left arm for covid-19 immunisation. The patient's relevant medical history included: "Osteoporosis" (unspecified if ongoing); "shrimp" (unspecified if ongoing). The patient's concomitant medications were not reported. Past drug history included: Neomycin, reaction(s): "known allergies: Neomycin". The following information was reported: INTERCHANGE OF VACCINE PRODUCTS (medically significant) with onset 02Nov2022, outcome "unknown", described as "Vaccine brand other: Moderna Bivalent/ vaccine brand: Pfizer / BioNTech"; VACCINATION FAILURE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "COVID test positive". Therapeutic measures were taken as a result of vaccination failure, covid-19.; Sender's Comments: Based on available information, a lack of efficacy (Vaccination failure and COVID-19) under Interchange of vaccine products with the suspect vaccine BNT162B2 in this patient cannot be completely excluded.